natgillin/translations-raw huggingface dataset:
Not known: Abnormal vision 
Očesne bolezni neznana: nenormalen vid
Luminity should be used within 12 hours following activation. 
Zdravilo Luminity morate uporabiti v 12 urah po aktiviranju.
If you have had an allergic reaction in the past with Luminity or any other ultrasound contrast agent tell your doctor. 
Če ste že kdaj prejeli zdravilo Luminity ali katero koli drugo kontrastno sredstvo, ki ga uporabljamo pri ultrazvočnih preiskavah, in se je pri tem pojavila alergijska reakcija, o tem obvestite svojega zdravnika.
Luminity contains sodium. 
Zdravilo Luminity vsebuje natrij.
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodiumfree' . 
Zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar dejansko pomeni, da je “brez natrija”.
- if you are allergic to perflutren or any of the other ingredients of Luminity. 
- če ste alergični na perflutren ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Gas and solvent for dispersion for injection/infusion 1 x 1.5 ml single-dose vial 4 x 1.5 ml single-dose vials 
plin in vehikel za disperzijo za injiciranje/infundiranje 1 x 1,5-ml viala z enim odmerkom
As Luminity has no pharmacologic effect, and on the basis of its pharmacokinetic and pharmacodynamic profiles, no or negligible influence is expected with the use of this product on the ability to drive or use machines. 
Glede na farmakokinetične in farmakodinamične lastnosti ni pričakovati vpliva na sposobnost vožnje in upravljanja s stroji oz. je pričakovani vpliv zanemarljiv.
Tell your doctor if you are pregnant or breast-feeding and ask your doctor or pharmacist for advice before you are given Luminity. 
Preden dobite zdravilo Luminity, morate zdravniku ali farmacevtu povedati, če ste noseči ali če dojite,
The product consists of lipid encapsulated perflutren microspheres. 
Zdravilo sestavljajo mikrosfere perflutrena, inkapsulirane z lipidom.
The product should be used within 12 hours of activation. 
Zdravilo je treba uporabiti v 12 urah po aktiviranju.
• rash, redness of the skin, 
• izpuščaj, pordelost kože,
Rare side effects (may affect up to 1 in 1000 people) 
Redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 bolnikov)
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). 
Študije na živalih ne kažejo na neposredne ali posredne škodljive vplive na nosečnost, razvoj zarodka/plodu,
Before administering Luminity, the medicinal product must be activated by using a mechanical shaking device, the Vialmix, see section 6.6. 
Pred uporabo je treba zdravilo Luminity aktivirati z uporabo mehanskega stresalnika Vialmix, glejte poglavje 6.6.
Patients should be closely monitored and administration should be under the direction of a physician experienced in the management of hypersensitivity reactions including severe allergic reactions, which might require resuscitation. 
Zdravilo se sme uporabljati le pod neposrednim nadzorom zdravnika, ki ima izkušnje z ukrepanjem v primeru pojava preobčutljivostnih reakcij, vključno s hudimi alergijskimi reakcijami,
The approximate amount of perflutren gas in each ml is 150 microlitres (μl). 
Približna količina plina perflutrena je 150 mikrolitrov (μl) na mililiter.
Preclinical data reveal no special hazard for humans based on conventional studies of genotoxicity, fertility, embryo/foetal development, parturition or post-natal development, and local tolerance. 
Predklinični podatki na osnovi običajnih študij genotoksičnosti, plodnosti, embrio-fetalnega razvoja, porajanja ali postnatalnega razvoja in lokalnega prenašanja ne kažejo posebnega tveganja za človeka.
The total dose of perflutren should not exceed 1.6 ml. 
Celotni odmerek perflutrena ne sme preseči
The systemic clearance of perflutren was similar in healthy and COPD subjects. 
Sistemski očistek perflutrena je bil pri zdravih osebah in bolnikih s KOPB podoben.
Caution must be exercised when considering the administration of Luminity to these patients. 
Zato se morate za uporabo zdravila Luminity pri takšnih bolnikih odločiti previdno.
Gas and solvent for dispersion for injection/infusion Colourless, uniformly clear to translucent liquid. 
plin in vehikel za disperzijo za injiciranje/infundiranje brezbarvna, enakomerno bistra do prosojna tekočina
• increased blood pressure, 
• omedlevica, • zvišan krvni tlak,
• altered heart rate, palpitations (you feel your heart beats harder or in an irregular way), 
• otrplost, mravljinčenje ali pekoč občutek, • spremenjen srčni utrip, palpitacije (občutek močnejšega ali nerednega bitja srca),
Overdose is not likely to happen since the medicine is administered by a doctor. 
Verjetnost prevelikega odmerjanja tega zdravila je majhna, saj vam ga bo injiciral zdravnik.
Not known: Cardiac arrest, ventricular arrhythmias (ventricular fibrillation, ventricular tachycardia, premature ventricular contactions), asystole, atrial fibrillation, cardiac ischaemia, supraventricular tachycardia, supraventricular arrhythmia 
Srčne bolezni redki: bradikardija, tahikardija, palpitacije neznana: srčni zastoj, ventrikularne aritmije (ventrikularna fibrilacija, ventrikularna tahikardija, prezgodnje krčenje prekatov), asistolija, atrijska fibrilacija, srčna ishemija,
In most subjects after 4-5 minutes, perflutren was undetectable in blood and expired air. Perflutren concentrations in blood were shown to decline in a mono-exponential fashion with a mean half-life of 1.3 minutes in healthy subjects and 1.9 minutes in COPD subjects. 
Ugotovljeno je, da koncentracija perflutrena v krvi upada monoeksponentno, in sicer s povprečnim razpolovnim časom, ki je pri zdravih preiskovancih 1,3 minute in pri preiskovancih s KOPB 1,9 minute.
The pharmacokinetic properties of Luminity were evaluated in normal healthy subjects and subjects with chronic obstructive pulmonary disease (COPD) following intravenous administration of a 50 µl/kg dose of the product. 
Farmakokinetične lastnosti zdravila Luminity so ocenili pri normalnih zdravih preiskovancih in pri preiskovancih s kronično obstruktivno pljučno boleznijo (KOPB) po intravenski aplikaciji odmerka
Extreme caution should be used when considering the administration of Luminity to patients with unstable cardiopulmonary status, for example: unstable angina, acute myocardial infarction, severe ventricular arrhythmias, severe heart failure (NYHA IV) or respiratory failure. 
Pri bolnikih z nestabilnim kardiopulmonalnim stanjem je treba zdravilo Luminity uporabljati izjemno previdno, npr. pri bolnikih z nestabilno angino pektoris, akutnim miokardnim infarktom, s hudo ventrikularno aritmijo, hudim srčnim popuščanjem
The reported adverse reactions following the use of Luminity in pivotal and supportive trials (total of 2,526 patients) occur within minutes after administration and usually resolve without therapeutic intervention within 15 minutes. 
bolnikih) so se pojavili v nekaj minutah po aplikaciji in so ponavadi v 15 minutah minili brez terapevtskega ukrepanja.
- The vial should be vented with a sterile syringe needle or a sterile non-siliconised mini-spike before withdrawing the dispersion. 
- Preden izvlečete disperzijo, zabodite v vialo sterilno injekcijsko iglo ali sterilno, nesilikonizirano mini-konico, da bo viala odzračena.
• breathing problems, cough, dry throat, difficulty in swallowing, 
• težave z dihanjem, kašelj, suho žrelo, težave s požiranjem,
The approximate amount of perflutren gas in each ml of Luminity is 150 microlitres. 
Približna količina plina perflutrena je 150 mikrolitrov na mililiter zdravila Luminity.
• fatigue, 
• utrujenost,
After activation: Do not store above 30°C. 
Po aktiviranju: Shranjujte pri temperaturi do 30 °C.
After activation (shaking), the product appears as a milky white liquid. 
Po aktiviranju (stresanju) ima videz mlečno bele disperzije.
Uncommon: Hypotension Rare: Syncope, hypertension, peripheral coldness 
Žilne bolezni pogosti: zardevanje občasni: hipotenzija redki: sinkopa, hipertenzija, hladne okončine
• abdominal pain, diarrhoea, nausea (feeling sick), vomiting, 
• bolečina v trebuhu, driska, navzea (siljenje na bruhanje), bruhanje,
After activation (shaking), do not store above 30°C. 
Po aktiviranju (stresanju) shranjujte pri temperaturi do 30 °C.
• difficulty in breathing, throat irritation, 
• težko dihanje, draženje žrela,
Elderly Pharmacokinetics has not been specifically studied in the elderly. 
Farmakokinetike pri starostnikih niso posebej preučevali.
Each ml contains a maximum of 6.4 x 109 perflutren-containing lipid bubbles, with an average diameter range of 1.1-2.5 micrometres. 
En mililiter vsebuje največ 6,4 x 109 lipidnih mehurčkov, ki vsebujejo perflutren; povprečni razpon njihovega premera je od 1,1 do 2,5 mikrometra.
• joint pain, pain on the side(s), neck pain, muscle cramp, fever, muscle stiffness 
• bolečina v sklepih, bolečina ob strani/ob straneh, bolečine v vratu, mišični krč, zvišana telesna temperatura, mišična togost in
Administration and mechanical activation procedure Luminity should not be administered by methods not specified in section 4.2 (e.g. intra-arterial injection). 
Zdravila Luminity se ne sme aplicirati na noben drug način (npr. intraarterijsko injiciranje).
• back pain, chest pain, 
• bolečina v hrbtu, bolečina v prsih,
Luminity is an ultrasound contrast-enhancing agent for use in adult patients in whom non-contrast echocardiography was suboptimal (suboptimal is considered to indicate that at least two of six segments in the 4- or 2-chamber view of the ventricular border were not evaluable) and who have suspected or established coronary artery disease, to provide opacification of cardiac chambers and improvement of left ventricular endocardial border delineation at both rest and stress. 
(pri projekciji “štirih” ali “dveh votlin” vsaj dveh od šestih segmentov prekatne stene ni bilo možno ovrednotiti), da bi tako dosegli opacifikacijo srčnih votlin in boljšo zamejitev endokardialne meje levega prekata tako v mirovanju kot med obremenitvijo.
1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) 1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid, monosodium salt (DPPA) N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3phosphatidylethanolamine, monosodium salt (MPEG5000 DPPE) Sodium dihydrogen phosphate monohydrate Disodium hydrogen phosphate heptahydrate Sodium chloride 
1,2-dipalmitoil-sn-glicero-3-fosfatidilholin (DPPC) 1,2-dipalmitoil-sn-glicero-3-fosfatidilna kislina, mononatrijeva sol (DPPA) N-(metoksipolietilenglikol 5000 karbamoil)-1,2-dipalmitoil-sn-glicero-3fosfatidiletanolamin, mononatrijeva sol (MPEG5000 DPPE) natrijev dihidrogenfosfat monohidrat natrijev hidrogenfosfat heptahidrat natrijev klorid propilenglikol glicerol voda za injekcije
Do not use Luminity after the expiry date which is stated on the carton and label after EXP. Before activation (shaking), store in a refrigerator (2°C - 8°C). 
Pred aktiviranjem (stresanjem) shranjujte v hladilniku (2 °C - 8 °C).
Single doses of up to 100 microlitres dispersion/kg and multiple doses up to 150 microlitres dispersion/kg were tolerated well in Phase I clinical trials. 
V kliničnih preskušanjih I. faze so bolniki dobro prenesli posamične odmerke do 100 mikrolitrov disperzije/kg in večkratne odmerke do 150 mikrolitrov disperzije/kg.
• itching, 
• omotica,
Total lung clearance (CLlung) of perflutren was shown to be no different in healthy subjects compared to COPD subjects. 
Ugotovljeno je, da se celotni pljučni očistek (CLpljučni) perflutrena med zdravimi preiskovanci in preiskovanci s KOPB ne razlikuje.
Serious immediate hypersensitivity reactions (eg: anaphylaxis, anaphylactic shock and anaphylactoid reactions, hypotension and angioedema) have been reported following the administration of Luminity. 
Po uporabi zdravila Luminity so poročali o pojavu resnih takojšnjih preobčutljivostnih reakcij (npr. anafilaksija, anafilaktični šok in anafilaktoidne reakcije, hipotenzija ter angioedem).
Each ml contains maximum 6.4 x 109 perflutren-containing lipid microspheres with a mean diameter range of 1.1-2.5 μm (approximately 150 microlitres perflutren gas per ml). 
NAVEDBA ENE ALI VEČ UČINKOVIN En mililiter vsebuje največ 6,4 x 109 perflutren vsebujočih lipidnih mikrosfer s povprečnim razponom premera od 1,1 do 2,5 μm (približno 150 mikrolitrov plina perflutrena na mililiter).
Luminity is then given into a vein either as a ‘bolus' injection (given all at once) or as an infusion (drip solution) after being diluted with sodium chloride 9 mg/ml (0.9%) or glucose 50 mg/ml (5%) solution for injection. 
Zdravilo Luminity se daje v veno kot injiciranje »bolusa« (celotni odmerek se vbrizga naenkrat) ali kot infundiranje (kapalna raztopina) po redčenju z raztopino za injiciranje z 9 mg/ml natrijevega klorida (0,9 %) ali 50 mg/ml glukoze (5 %).
Pharmacotherapeutic group: ultrasound contrast media, microspheres of phospholipids, ATC Code: V08DA04 
5.1 Farmakodinamične lastnosti Farmakoterapevtska skupina: ultrazvočna kontrastna sredstva, mikrosfere fosfolipidov,
Patients with adult respiratory distress syndrome, endocarditis, prosthetic heart valves, systemic inflammation, sepsis, hyperactive coagulation and/or recurrent thromboembolism Luminity should be used only after careful consideration and such use should be monitored closely during administration in patients with adult respiratory distress syndrome, endocarditis, a heart with prosthetic valves, acute states of systemic inflammation or sepsis, known states of hyperactive coagulation and/or recurrent thromboembolism. 
Zdravilo Luminity se sme uporabljati le po skrbnem premisleku pri bolnikih s sindromom dihalne stiske pri odraslem, z endokarditisom, umetnimi srčnimi zaklopkami, akutnimi stanji sistemskega vnetja ali sepso, znanimi stanji hiperaktivnosti sistema koagulacije in/ali ponavljajočo se trombembolijo.
Excipients: 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid, monosodium salt (DPPA), N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, monosodium salt (MPEG5000 DPPE), sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate heptahydrate, sodium chloride, propylene glycol, glycerol, water for injections 
Pomožne snovi: 1,2-dipalmitoil-sn-glicero-3-fosfatidilholin (DPPC), 1,2-dipalmitoil-sn-glicero-3fosfatidilna kislina, mononatrijeva sol (DPPA), N-(metoksipolietilenglikol 5000 karbamoil)-1,2dipalmitoil-sn-glicero-3-fosfatidiletanolamin, mononatrijeva sol (MPEG5000 DPPE), natrijev dihidrogenfosfat monohidrat, natrijev hidrogenfosfat heptahidrat, natrijev klorid, propilenglikol, glicerol, voda za injekcije
Before administering the product, it must be activated by using the Vialmix, a mechanical shaking device. 
Pred apliciranjem je treba zdravilo Luminity aktivirati z Vialmixom, mehanično napravo za stresanje.
- The other ingredients are 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), 1,2dipalmitoyl-sn-glycero-3-phosphatidic acid, monosodium salt (DPPA), N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, monosodium salt (MPEG5000 DPPE), sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate heptahydrate, sodium chloride, propylene glycol, glycerol and water for injections. 
Pomožne snovi so 1,2-dipalmitoil-sn-glicero-3-fosfatidilholin (DPPC), 1,2-dipalmitoil-sn-glicero-3fosfatidilna kislina, mononatrijeva sol (DPPA), N-(metoksipolietilenglikol 5000 karbamoil)-1,2dipalmitoil-sn-glicero-3-fosfatidiletanolamin, mononatrijeva sol (MPEG5000 DPPE), natrijev dihidrogenfosfat monohidrat, natrijev hidrogenfosfat heptahidrat, natrijev klorid, propilenglikol, glicerol in voda za injekcije.
The recommended dose via an intravenous infusion is 1.3 ml dispersion added to 50 ml of sodium chloride 9 mg/ml (0.9%) or glucose 50 mg/ml (5%) solution for injection. 
Priporočeni odmerek intravenske infuzije je 1,3 ml disperzije, dodane 50 ml 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje ali 50 mg/ml (5 %) raztopine glukoze za injiciranje.
Luminity should only be administered by trained physicians with technical expertise in performing and interpreting contrast echocardiograms, and appropriate resuscitation equipment should be available in case of cardiopulmonary or hypersensitivity reactions (see section 4.4). 
Zaradi možnega pojava kardiopulmonalnih ali preobčutljivostnih reakcij je pri uporabi zdravila Luminity treba imeti na voljo ustrezno opremo za oživljanje (glejte poglavje 4.4).
• peripheral coldness, 
• hladne okončine,
How to store Luminity 
Shranjevanje zdravila Luminity
Abnormal respiration, heart rate changes and decreased activity were observed soon after intravenous injection of Luminity at doses ≥ 0.3 ml/kg in single and repeat-dose toxicity studies in rats and monkeys. 
V študijah toksičnosti posamičnih in ponavljajočih se odmerkov pri podganah in opicah so po intravenskem injiciranju zdravila Luminity v odmerkih ≥ 0,3 ml/kg opažali nenormalno dihanje,
Therefore, caution should be exercised when Luminity is administered to breast-feeding women. 
V primeru uporabe zdravila Luminity pri doječih ženskah je zato potrebna previdnost.
Microspheres in the 1 to < 10 µm diameter size range contribute to the contrast effect by generating strongly enhanced echoes. 
< 10 µm močno ojačijo odboj in tako pripomorejo h kontrastnemu učinku.
Rare: Arthralgia, flank pain, neck pain, muscle cramp Not known: Muscle spasm, musculoskeletal pain, musculoskeletal discomfort, myalgia, hypertonia 
Bolezni mišično-skeletnega sistema in vezivnega tkiva občasni: bolečina v hrbtu redki: artralgija, bolečina v bokih, bolečina v vratu, mišični krč neznana pogostnost: mišični spazem, mišičnoskeletna bolečina, mišičnoskeletno neudobje, mialgija, hipertonija
As Luminity consists of microspheres that are stable and small enough for transpulmonary passage, enhanced echo signals in the left heart and systemic circulation are obtained. 
Zdravilo Luminity sestavljajo mikrosfere, ki so stabilne in dovolj majhne, da preidejo skozi pljuča.
Before activation (shaking) the contents of the vial, Luminity appears as a colourless, uniformly clear to translucent liquid. 
(stresanjem) vsebine viale je zdravilo Luminity brezbarvna, enakomerno bistra do prosojna tekočina.
Uncommon: Pruritus, increased sweating Rare: Rash, urticaria, erythema, erythematous rash 
Bolezni kože in podkožja občasni: srbenje, močnejše znojenje redki: izpuščaj, urtikarija, eritem, eritematozen izpuščaj
Each ml contains a maximum of 6.4 x 109 perflutren-containing lipid microspheres, with a mean diameter range of 1.1-2.5 micrometres (μm). 
KAKOVOSTNA IN KOLIČINSKA SESTAVA En mililiter vsebuje največ 6,4 x 109 lipidnih mikrosfer, ki vsebujejo perflutren; povprečni razpon premera mikrosfer je od 1,1 do 2,5 mikrometra (μm).
For such patients monitoring should include vital sign measurements, electrocardiography, and, if clinically appropriate, cutaneous oxygen saturation. 
elektrokardiografijo in saturacijo s kisikom (perkutano), če je to klinično potrebno.
Hepatic impairment Pharmacokinetics has not been specifically studied in the hepatic disease patients. 
Farmakokinetike pri bolnikih z boleznimi jeter niso posebej preučevali.
Bolus intravenous injection using fundamental imaging technique at rest: 
Bolusno intravensko injiciranje z uporabo nelinearnega načina kontrastnega slikanja v mirovanju in med obremenitvijo:
Uncommon: Chest Pain, fatigue, feeling hot, injection site pain Rare: Pyrexia, rigors 
Splošne težave in spremembe na mestu aplikacije občasni: bolečina v prsih, utrujenost, občutek vročine, bolečina na mestu injiciranja redki: pireksija, mrzlica
- Luminity may be diluted with sodium chloride 9 mg/ml (0.9%) solution for injection or glucose 50 mg/ml (5%) solution for injection. 
- Zdravilo Luminity lahko razredčite z 9 mg/ml (0,9 %) raztopino natrijevega klorida za injiciranje ali s 50 mg/ml (5 %) raztopino glukoze za injiciranje.
Renal impairment Pharmacokinetics has not been specifically studied in the renal disease patients. 
Okvara ledvic Farmakokinetike pri bolnikih z boleznimi ledvic niso posebej preučevali.
Luminity 150 microlitres/ml gas and solvent for dispersion for injection/infusion perflutren 
Luminity 150 mikrolitrov/ml plin in vehikel za disperzijo za injiciranje/infundiranje perflutren
Bolus intravenous injection using non-linear contrast imaging technique at rest and stress: The recommended dose is multiple injections of 0.1 to 0.4 ml of dispersion, followed by a 3 to 5 ml bolus of sodium chloride 9 mg/ml (0.9%) or glucose 50 mg/ml (5%) solution for injection to maintain optimal contrast enhancement. 
Priporočeni odmerek je več injekcij od 0,1 do 0,4 ml disperzije, ki jim sledi bolus od 3 do 5 ml 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje ali 50 mg/ml (5 %) raztopine glukoze za injiciranje za ohranitev optimalne ojačitve kontrasta.
Luminity 150 microlitres/ml gas and solvent for dispersion for injection/infusion 
Luminity 150 mikrolitrov/ml plin in vehikel za disperzijo za injiciranje/infundiranje
Immune system disorders Not known: Allergic type reactions, anaphylaxis, anaphylactic shock and anaphylactoid type reactions, hypotension, angioedema, lip swelling, bronchospasm, rhinitis, upper airway swelling, throat tightness, facial swelling, eye swelling 
angioedem, otekanje ustnic, bronhospazem, rinitis, otekanje zgornjih dihal, tesnost grla, otekanje obraza, otekanje očesa
Luminity is used in patients with suspected or confirmed coronary artery disease (obstruction of the blood vessels supplying the heart muscle), when the image obtained with noncontrast echocardiography is not optimal. 
ki oskrbujejo srčno mišico) ali sumom nanjo, kadar slika, ki se pridobi z ehokardiografijo brez kontrastnega sredstva, ni optimalna.
Store in a refrigerator (2°C - 8°C) For storage conditions after activation of the medicinal product, see section 6.3. 
Za pogoje shranjevanja po aktiviranju zdravila glejte poglavje 6.3.
If necessary, a second 10 microlitre dispersion/kg dose followed by a second 10 ml bolus of sodium chloride 9 mg/ml (0.9%) or glucose 50 mg/ml (5%) solution for injection may be administered 5 minutes after the first injection to prolong contrast enhancement. 
Če je potrebno, lahko za podaljšanje ojačitve kontrasta 5 minut po prvi injekciji aplicirate drugi odmerek 10 mikrolitrov disperzije/kg, ki mu sledi drugi 10-ml bolus 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje ali 50 mg/ml (5 %) raztopine glukoze za injiciranje.
Rare: Respiratory Distress, Cough, Dry Throat Not known: Respiratory arrest, decreased oxygenation, hypoxia, Gastrointestinal disorders Uncommon: Abdominal Pain, diarrhoea, nausea, vomiting, 
Bolezni dihal, prsnega koša in mediastinalnega prostora občasni: dispneja, draženje žrela redki: dihalna stiska, kašelj, suho žrelo neznana pogostnost: zastoj dihanja, zmanjšana oksigenacija, hipoksija
Rare: Paraesthesia 
• otrplost obraza
Eye disorders 
• otekanje oči
Do not store the vial above 30°C following activation. 
Po aktiviranju hranite vialo pri temperaturi do 30 °C.
Propylene glycol 
Okvara jeter
Package leaflet: Information for the user Luminity 150 microlitres/ml gas and solvent for dispersion for injection/infusion perflutren 
Navodilo za uporabo Luminity 150 mikrolitrov/ml plin in vehikel za disperzijo za injiciranje/infundiranje perflutren
Patients with unstable cardiopulmonary status 
Bolniki s srčnimi spoji (šanti)
Luminity has not been specifically studied in patients with hepatic impairment. 
Pri bolnikih z okvaro jeter uporabe zdravila Luminity niso posebej proučevali.
Respiratory, thoracic and mediastinal disorders 
supraventrikularna tahikardija, supraventrikularna aritmije
The recommended dose is 10 microlitre dispersion/kg by slow bolus intravenous injection, followed by a 10 ml bolus of sodium chloride 9 mg/ml (0.9%) or glucose 50 mg/ml (5%) solution for injection. 
10-ml bolus 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje ali 50 mg/ml (5 %) raztopine glukoze za injiciranje.
Luminity has not been specifically studied in elderly patients. 
Pri starostnikih uporabe zdravila Luminity niso posebej proučevali.